Was some good information in today’s webinar - on track to complete between sept-Nov . The part I found most interesting was regarding pricing on triage screening . I under estimated just how big that indication alone is . 1 million women a year at $900 USD per test (at very low COGS so excellent margin) and there was mention of our pricing potentially being a premium to that given its superior spec/sens. That’s over $1 bill end market alone excluding ROW markets !
In addition being an immunoassay test , the scalability of it is going to be very easy compared to others on the market as all path labs have this already .
Also sounds like the screening indication which is the big fish is progressing nicely also . I suspect we see a lot more interest in the share price as we approach q4.
COV Price at posting:
37.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)